We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$885M
AUM Growth
-$109M
Cap. Flow
-$6.3M
Cap. Flow %
-0.71%
Top 10 Hldgs %
99.96%
Holding
11
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$4.34M
2
MRSN
Mersana Therapeutics
MRSN
+$1.97M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$314M 35.43%
14,040,000
– –
BIIB icon
2
Biogen
BIIB
$30B
$172M 19.4%
643,000
– –
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$170M 19.19%
16,390,000
– –
GILD icon
4
Gilead Sciences
GILD
$162B
$78.5M 8.88%
1,273,100
-68,800
-5% -$4.34M
INVA icon
5
Innoviva
INVA
$1.55B
$76.8M 8.68%
6,614,000
– –
MRSN
6
DELISTED
Mersana Therapeutics
MRSN
$27M 3.05%
159,880
-12,092
-7% -$1.97M
AMRN
7
Amarin Corp
AMRN
$298M
$26.2M 2.96%
1,199,900
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$17.5M 1.98%
1,390,790
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$2.46M 0.28%
30,900
– –
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$1.02M 0.12%
500,356
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$315K 0.04%
185,183
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Sarissa Capital Management held 11 positions worth $885M, down 11% from $993M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2022: portfolio turnover was 0%. Sarissa Capital Management opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's biggest Q3 2022 reduction was Gilead Sciences, cutting an estimated $4.34M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $885M portfolio in Q3 2022.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q3 2022.
  • Sarissa Capital Management's portfolio value fell 11% quarter-over-quarter to $885M.

Based on Sarissa Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.